It’s only fair to share… Camibirstat CAS 2671128-05-3 N-{(2S)-1-[(4-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl}-1,3-thiazol-2-yl)amino]-3-methoxy-1-oxopropan-2-yl}-1-(methanesulfonyl)-1H-pyrrole-3-carboxamideATPase inhibitor, antineoplastic MW C24H30N6O6S2 MF 562.7 g/mol Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.[1] It is being developed by Foghorn Therapeutics.[2] Camibirstat …